Antigenics to Present at the UBS 2008 Global Life Sciences Conference

Listen to a webcast of this event

New York — September 15, 2008 — Antigenics Inc. (NASDAQ: AGEN) today announced that Garo Armen, Ph.D., the company’s chairman and chief executive officer, will present at the UBS 2008 Global Life Sciences Conference at the Grand Hyatt New York on Monday, September 22, 2008 at 8:00 a.m. Eastern Time.

Dr. Armen will provide an overview of the company and its priority development programs, including Oncophage® (vitespen) therapeutic cancer vaccine and QS-21™ vaccine adjuvant.

The audio portion of the presentation will be webcast live on the company’s website at www.antigenics.com and will be archived there for approximately 30 days following the presentation.

About Antigenics

Antigenics (NASDAQ: AGEN) is a biotechnology company working to develop treatments for cancers and infectious diseases. The company’s investigational product portfolio includes Oncophage®, a patient-specific therapeutic cancer vaccine being evaluated in several indications; Aroplatin™ (L-NDDP), a liposomal, third-generation platinum chemotherapeutic; AG-707, a therapeutic vaccine for the treatment of genital herpes; and QS-21 Stimulon®, an adjuvant being evaluated by Antigenics’ collaborative partners in approximately 15 clinical stage vaccines. For more information, please visit www.antigenics.com.

CONTACTS
Media: Sunny Uberoi, 212.994.8206 or 917.443.3325
Investors: Robert Anstey, 800.962.2436